Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: $51.00 (24.18% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetActions
3/17/2015Credit SuisseBoost Price Target$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2013Cowen and CompanyLower Price TargetOutperform$47.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/16/2013Cowen and CompanyBoost Price TargetOutperform$45.37 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2013Sanford C. BernsteinInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2013Cowen and CompanyInitiated CoverageOutperform$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2013Credit SuisseReiterated RatingOutperform$30.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2013William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2013Morgan StanleyReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/28/2013 forward)